Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia
Frontiers in Bioscience-Landmark · 22.01.2025 · 30 (1)
DOI: 10.31083/fbl26721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 22.01.2025. Verfasst von Yixiao Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China. Hauptthemen laut MEDLINE: Dexamethasone, Neutrophils, Nanoparticles, Pneumonia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cisen Pharmaceutical Public COVID-19 Scientific Research Fund.
Abstract (Originalsprache)
Background
Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use. Neutrophil cell membrane-derived nanovesicles, with their ability to specifically target hyper-activated immune cells and excellent mucus permeability, emerge as a promising carrier for pulmonary inhalation therapy.
Methods
We designed a novel UiO66 metal-organic framework nanoparticle loaded with Dex and coated with neutrophil cell membranes (UiO66-Dex@NMP) for targeted therapy of severe pneumonia. This was achieved by loading Dex into UiO66 pores and subsequently coating with neutrophil membranes for functionalization.
Results
Drug release experiments revealed UiO66-Dex@NMP to exhibit favorable sustained-release properties. Additionally, UiO66-Dex@NMP demonstrated excellent targeting capabilities both in vitro and in vivo. In a mouse model of lipopolysaccharide (LPS)-induced pneumonia, UiO66-Dex@NMP significantly reduced lung inflammation compared to both the control model and Dex administered via inhalation. Histopathological analysis further confirmed UiO66-Dex@NMP’s ability to alleviate lung tissue damage.
Conclusions
UiO66-Dex@NMP represents a novel and safe inhaled delivery carrier for Dex, offering valuable insights into the clinical management of respiratory diseases, including severe pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China.
- Institute of Burn Research, The First Affiliated Hospital, State Key Lab of Trauma, Burn and Combined Injury, Chongqing Key Laboratory for Disease Proteomics, Third Military Medical University (Army Medical University),…
- Department of Respiratory and Critical Care Medicine, Zibo Municipal Hospital, 255400 Zibo, Shandong, China.
- MPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Medical College, Nantong University, 226001 Nantong, Jiangsu, China.
- Department of Breast Thyroid Surgery, Zibo Central Hospital, 255036 Zibo, Shandong, China.
Förderung
- Cisen Pharmaceutical Public COVID-19 Scientific Research Fund
Zitieren
APA
Yang, Y., Yan, L., Zhang, H., Xiao, C., & Wang, K. (2025). Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia. Frontiers in Bioscience-Landmark, 30(1). https://doi.org/10.31083/fbl26721
Vancouver
Yang Y, Yan L, Zhang H, Xiao C, Wang K. Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia. Frontiers in Bioscience-Landmark. 2025;30(1). doi:10.31083/fbl26721
BibTeX
@article{Yang2025,
author = {Yang, Yixiao and Yan, Lizhen and Zhang, Han and Xiao, Chuanguang and Wang, Kai},
title = {Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
volume = {30},
number = {1},
doi = {10.31083/fbl26721}
}
EUVIMED